

Proposal by the nomination committee prior to the 2024 annual general meeting of Sedana Medical AB (publ)

The nomination committee's establishment

At the annual general meeting on May 10 2021, it was resolved to adopt principles for the nomination of and instructions for the nomination committee of Sedana Medical AB (publ) ("Sedana Medical" or the "Company").

Prior to the annual general meeting 2024, the nomination committee of the Company consists of the following members:

- Karl Tobieson, chairman of the nomination committee and appointed by Linc AB;
- Claus Bjerre, chairman of the board;
- Patrik Walldov, utsedd av Anders Walldov (including indirect holding via Brohuvudet AB)
- Monica Åsmyr, appointed Swedbank Robur Fonder.

The nomination committee represents approximately 30% of all voting rights in the company.

The nomination committee has presented the following resolution proposals under items 2 and 9–11 on the proposed agenda for the general meeting.

Election of chair of the general meeting (item 2)

The nomination committee proposes that Karl Tobieson is elected chairman of the annual general meeting 2024 or, in the event he is prevented from participating, that the person appointed by the board of directors shall be elected chairman of the meeting.

Determination of the number of board members and deputies and auditors and deputy auditors (item 9)

The board of directors of the Company currently consists of five ordinary board members without deputy board members. The nomination committee proposes that the board of directors of the Company shall, for the period until the end of the next annual general meeting, be comprised of five ordinary board members without deputy members.

The Company currently has one auditor (a registered audit firm) without any deputy auditors. The nomination committee proposes that the Company shall continue to have one auditor (a registered audit firm) without any deputy auditor.

Determination of fees to the board members and the auditors (item 10)

The nomination committee proposes that, for the period until the end of the next annual general meeting, fees payable to the board of directors shall amount to SEK 785,000 (previously SEK 625,000) for the chairman of the board and SEK 250,000 (previously SEK 250,000 for each of the other board members) for each of the other board members elected by the general meeting. Furthermore, the nomination committee proposes that fees payable for work on the audit committee of the board of directors shall amount to SEK 75,000 for the chairman of the audit committee and SEK 30,000 for each of the other members. The nomination committee's proposal implies an overall increase in fees payable for work on the board of directors and its committees of SEK 160 000 (corresponding to an increase of approximately 9 per cent) compared to the total fees resolved by the annual general meeting 2023, under the assumption

that the nomination committee's proposal in respect of election of board of directors is approved and that the audit committee will continue to be composed of three members.

The nomination committee proposes that fees payable to the auditors shall be paid in accordance with approved invoices within the frame of the quotation.

Election of the board members as well as chairman of the board and auditors (item 11)

The board of directors of the Company currently consists of the ordinary members Claus Bjerre (chairman), Hilde Furberg, Ola Magnusson, Christoffer Rosenblad and Eva Walde, who have all been elected by the general meeting. The nomination committee proposes re-election of Claus Bjerre, Hilde Furberg, and Christoffer Rosenblad, as ordinary board members and new election of Jens Viebke and Donna Haire, as ordinary board members, for the period until the end of the next annual general meeting. Ola Magnusson and Eva Walde have declined re-election.

The nomination committee further proposes re-election of Claus Bjerre as chairman of the board of directors.

The nomination committee proposes re-election of the registered audit firm Öhrlings PricewaterhouseCoopers AB as auditor of the Company for the period until the end of the next annual general meeting. If Öhrlings PricewaterhouseCoopers AB is elected as auditor, the chartered accountant Lars Kylberg will be the auditor-in-charge.

About Jens Viebke

Jens Viebke who is proposed to be elected as new ordinary board member, is Executive Vice President Corporate Development at Getinge AB, and before that held positions as President of Acute Care Therapies and also as the President of the Critical Care and Vascular Systems divisions in the Medical Systems business area. Jens has long and broad experience from the healthcare industry and has previously held positions in research and development, as well as strategy and marketing, at large companies in the healthcare industry, including GE Healthcare and Pharmacia & Upjohn. Jens has a PhD in Polymer Technology from the Royal Institute of Technology of Stockholm and holds an Executive MBA from the Stockholm School of Economics.

About Donna Haire

Donna Haire who is proposed to be elected as new ordinary board member, is CEO of The Eriah Group, Inc. She is an executive with over 30 years of experience in healthcare, pharmaceutical, and medical device industries. She has extensive experience in regulatory, quality, clinical affairs, business development, and R&D. Donna Haire has held positions as Executive Vice President at On Target Laboratories, Vice President, Head of Medical Care Global Regulatory Affairs at Bayer, Senior Vice President of Regulatory, Quality, Clinical, and Medical Affairs at AngioDynamics and has held senior level positions at Philips Healthcare and Medtronic. Donna was an Adjunct Professor at the University of Akron School of Law. She served as an AdvaMed Technical and Regulatory Board Committee Member. Donna was designated a U.S. regulatory expert to lead multiple international trade negotiations in regulatory convergence. Donna has an M.S. in Biology from Cleveland State University and a B.S. in Biology from The University of Akron.

Reasoned statement by the nomination committee

The nomination committee has since its establishment held five formal meetings, with numerous additional interactions via phone and e-mail including interviews with the board of directors. The nomination committee has received a report from the chairman of the board of directors on how the work has been conducted in the board of directors as a whole and in the audit committee and has discussed the work of the board of directors and the audit committee with members of the board of directors. The chairman of the board of directors has provided an account of the completed evaluation of the board's work and the nomination committee has reviewed and discussed this evaluation.

Prior to the annual general meeting 2024, the nomination committee has discussed in detail the requirements in terms of diversifications regarding competences, experience and background that may be placed on the board of directors of Sedana Medical, taking into account, among other things, the Company's situation, strategic development, governance and control as well as the size, breadth and diversity of competence, international experience, age, gender, background and experience. In addition, independency matters have been taken into account in the nomination committee's discussions, and an assessment has also been made of the capacity of each individual board member to devote sufficient time and commitment to the work of the board of directors.

The nomination committee has, in its work before the annual general meeting, had an objective to ensure that the board of directors, as a group, has the necessary competence and experience, in particular for Sedana Medical's operations and developing stage, and to be able to continue to lead the Company in a successful manner. The nomination committee has in particular taken into account the need for diversity and variety in terms of competence, experience and background, in consideration of, inter alia, the Company's strategic development, direction and control.

The nomination committee finds that the work of the board of directors has been performed well and that the board of directors has been appropriately composed in terms of the members' competences, experience and range regarding background and qualifications. Sedana Medical is transforming from being a medical device company to also cover pharmaceutical business and is in the launch phase for its pharmaceutical product in Europe and is also conducting clinical trials in US. Given this situation, the nomination committee has an objective to maintain the international profile of the board of directors, placing particular emphasis on commercial experience, network and skills.

It is the view of the nomination committee that the proposed size and composition of the board of directors provides the conditions to monitor, challenge and support the management of the Company regarding strategy formulation and implementation, operations and future development effectively. The nomination committee's proposal for the board of directors means that all five members have strong life science experience and that a majority have marketing experience for either medical devices or pharmaceuticals. The nomination committee strives for diversity in several aspects, primarily gender and international industry experience. Of the proposed board members, three are men and two are women, which in the opinion of the nomination committee, is consistent with the gender balance requirement.

The nomination committee complies with the Swedish Corporate Governance Code (the "Code"). When assessing the independence of the proposed board members, the nomination committee has found that the proposed composition of the board of directors fulfills the requirements regarding independence set forth in the Code. In relation to the composition of the board of directors, the provisions of rule 4.1 of the

Code have been applied as diversity policy and with regard to the objectives of that policy, which has resulted in the nomination committee's proposal for the annual general meeting 2024 regarding the election of the board of directors.